National Pharmaceutical Pricing Authority fixes retail price of 28 new drugs

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 28 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-diabetic, anti-hypertensive, and respiratory medicines.

The pricing authority fixed the prices of around nine anti-diabetic formulations in its latest meeting. The price approval has been announced for formulations containing dapagliflozin, sitagliptin, empagliflozin, linagliptin, teneligliptin, glimepiride, and metformin hydrochloride extended release (ER) in different combinations and strengths.

These prices were approved by the authority following applications from companies including Alembic Pharmaceuticals, Corona Remedies, Jagsonpal Pharmaceuticals, Primus Remedies, Ipca Laboratories, and Glenmark Pharmaceuticals.

Prices has been fixed for almost ten anti-hypertensive formulations including particular strengths of combination of metoprolol succinate (ER), amlodipine and telmisartan from Sun Pharma Laboratories; amlodipine and valsartan tablets from Alembic Pharmaceuticals; and various combinations and strengths of telmisartan from SRK Puremed, Aristo Pharmaceuticals, and Unison Pharmaceuticals.

Retail price of a particular strength of respiratory medicine levocetrizine hydrochloride and montelukast syrup from Cipla Ltd; pain relief combination mefenamic acid and paracetamol tablets from Dr Reddy's Laboratories; two formulations of pantoprazole for injection (lyophilised) manufactured by Gufic Biosciences; a combination of theophylline anhydrous and montelukast sodium for long term management of chronic obstructive pulmonary disease (COPD) from the marketer Zydus Healthcare; alginate raft-forming oral suspension for gastroesophageal reflux disease (GERD) from German Remedies Pharmaceuticals, among others have also been fixed by the price regulator in its latest meeting held on October 30, 2025.

These are new drugs, under paragraph 2(1)(u) of the Drugs Prices Control Order (DPCO), 2013.

Under the Paragraph 2(1)(u) of the DPCO, 2013, a new drug is defined as a formulation launched by an existing manufacturer of a drug of specified dosages and strengths as listed in the National List of Essential Medicines (NLEM) by combining the drug with another drug either listed or not listed in the NLEM or a formulation launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as listed in the NLEM.

The methodology of calculating and fixing the retail price of new drugs for existing manufacturers of scheduled formulations are specified in the Para 5 and 15 of the DPCO, 2013, which is followed by the NPPA to arrive at the price against the applications submitted by the companies.

In case the retail price of any of these formulations are not complied with, as per the price notifications and notes released by the authority, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, added the price regulator.

News Source:

https://www.pharmabiz.com/NewsDetails.aspx?aid=182247&sid=1